Report Content
Chapter 1 Methodology
1.1 Methodology
1.2 Market definitions
1.3 Forecast parameters
1.4 Data sources
1.4.1 Secondary
1.4.1.1 Paid sources
1.4.1.2 Unpaid sources
1.4.2 Primary
Chapter 2 Executive Summary
2.1 Isothermal Nucleic Acid Amplification Technology (INAAT) testing industry 360° synopsis, 2017 - 2028
2.1.1 Business trends
2.1.2 Technology trends
2.1.3 Products trends
2.1.4 Application trends
2.1.5 End-use trends
2.1.6 Regional trends
Chapter 3 Isothermal Nucleic Acid Amplification Technology (INAAT) Industry Insights
3.1 Industry segmentation
3.2 Industry landscape, 2017 - 2028
3.3 Industry impact forces
3.3.1 Growth drivers
3.3.1.1 Rising prevalence of infectious diseases
3.3.1.2 Increasing adoption of INAAT over PCR
3.3.1.3 Increasing blood transfusion
3.3.1.4 Rise in demand for low-cost and effective diagnostics procedures
3.3.1.5 Technological advancements to boost market growth
3.3.2 Industry pitfalls & challenges
3.3.2.1 Lack of awareness about new diagnostics technologies
3.3.2.2 Opposition from PCR technologies will pose a major challenge
3.4 Growth potential analysis
3.4.1 By technology
3.4.2 By product
3.4.3 By application
3.4.4 By end-use
3.5 COVID-19 impact analysis
3.6 Porter’s analysis
3.7 Competitive landscape, 2021
3.7.1 Company matrix analysis, 2021
3.8 PESTEL analysis
Chapter 4 Isothermal Nucleic Acid Amplification Technology (INAAT) Market, By Technology
4.1 Key segment trends
4.2 Loop-mediated Isothermal Amplification (LAMP)
4.2.1 Market size, by region, 2017 - 2028 (USD Million)
4.3 Strand Displacement Amplification (SDA)
4.3.1 Market size, by region, 2017 - 2028 (USD Million)
4.4 Nucleic Acid Sequence-based Amplification (NASBA)
4.4.1 Market size, by region, 2017 - 2028 (USD Million)
4.5 Helicase-dependent Amplification (HDA)
4.5.1 Market size, by region, 2017 - 2028 (USD Million)
4.6 Others
4.6.1 Market size, by region, 2017 - 2028 (USD Million)
Chapter 5 Isothermal Nucleic Acid Amplification Technology (INAAT) Market, By Product
5.1 Key segment trends
5.2 Instruments
5.2.1 Market size, by region, 2017 - 2028 (USD Million)
5.3 Reagents
5.3.1 Market size, by region, 2017 - 2028 (USD Million)
Chapter 6 Isothermal Nucleic Acid Amplification Technology (INAAT) Market, By Application
6.1 Key segment trends
6.2 Infectious disease
6.2.1 Market size, by region, 2017 - 2028 (USD Million)
6.2.2 HIV
6.2.2.1 Market size, by region, 2017 - 2028 (USD Million)
6.2.3 Influenza
6.2.3.1 Market size, by region, 2017 - 2028 (USD Million)
6.2.4 Malaria
6.2.4.1 Market size, by region, 2017 - 2028 (USD Million)
6.2.5 Tuberculosis
6.2.5.1 Market size, by region, 2017 - 2028 (USD Million)
6.3 Oncology
6.3.1 Market size, by region, 2017 - 2028 (USD Million)
6.4 Blood Screening
6.4.1 Market size, by region, 2017 - 2028 (USD Million)
6.5 Others
6.5.1 Market size, by region, 2017 - 2028 (USD Million)
Chapter 7 Isothermal Nucleic Acid Amplification Technology (INAAT) Market, By End-use
7.1 Key segment trends
7.2 Hospitals
7.2.1 Market size, by region, 2017 - 2028 (USD Million)
7.3 Diagnostic Laboratories
7.3.1 Market size, by region, 2017 - 2028 (USD Million)
7.4 Others
7.4.1 Market size, by region, 2017 - 2028 (USD Million)
Chapter 8 Isothermal Nucleic Acid Amplification Technology (INAAT) Market, By Region
8.1 Key regional trends
8.2 North America
8.2.1 Market size, by country, 2017 - 2028 (USD Million)
8.2.2 Market size, by technology, 2017 - 2028 (USD Million)
8.2.3 Market size, by product, 2017 - 2028 (USD Million)
8.2.4 Market size, by application, 2017 - 2028 (USD Million)
8.2.4.1 Market size, by infectious disease, 2017 - 2028 (USD Million)
8.2.5 Market size, by end-use, 2017 - 2028 (USD Million)
8.2.6 U.S.
8.2.6.1 Market size, by technology, 2017 - 2028 (USD Million)
8.2.6.2 Market size, by product, 2017 - 2028 (USD Million)
8.2.6.3 Market size, by application, 2017 - 2028 (USD Million)
8.2.6.3.1 Market size, by infectious disease, 2017 - 2028 (USD Million)
8.2.6.4 Market size, by end-use, 2017 - 2028 (USD Million)
8.2.7 Canada
8.2.7.1 Market size, by technology, 2017 - 2028 (USD Million)
8.2.7.2 Market size, by product, 2017 - 2028 (USD Million)
8.2.7.3 Market size, by application, 2017 - 2028 (USD Million)
8.2.7.3.1 Market size, by infectious disease, 2017 - 2028 (USD Million)
8.2.7.4 Market size, by end-use, 2017 - 2028 (USD Million)
8.3 Europe
8.3.1 Market size, by country, 2017 - 2028 (USD Million)
8.3.2 Market size, by technology, 2017 - 2028 (USD Million)
8.3.3 Market size, by product, 2017 - 2028 (USD Million)
8.3.4 Market size, by application, 2017 - 2028 (USD Million)
8.3.4.1 Market size, by infectious disease, 2017 - 2028 (USD Million)
8.3.5 Market size, by end-use, 2017 - 2028 (USD Million)
8.3.6 Germany
8.3.6.1 Market size, by technology, 2017 - 2028 (USD Million)
8.3.6.2 Market size, by product, 2017 - 2028 (USD Million)
8.3.6.3 Market size, by application, 2017 - 2028 (USD Million)
8.3.6.3.1 Market size, by infectious disease, 2017 - 2028 (USD Million)
8.3.6.4 Market size, by end-use, 2017 - 2028 (USD Million)
8.3.7 UK
8.3.7.1 Market size, by technology, 2017 - 2028 (USD Million)
8.3.7.2 Market size, by product, 2017 - 2028 (USD Million)
8.3.7.3 Market size, by application, 2017 - 2028 (USD Million)
8.3.7.3.1 Market size, by infectious disease, 2017 - 2028 (USD Million)
8.3.7.4 Market size, by end-use, 2017 - 2028 (USD Million)
8.3.8 France
8.3.8.1 Market size, by technology, 2017 - 2028 (USD Million)
8.3.8.2 Market size, by product, 2017 - 2028 (USD Million)
8.3.8.3 Market size, by application, 2017 - 2028 (USD Million)
8.3.8.3.1 Market size, by infectious disease, 2017 - 2028 (USD Million)
8.3.8.4 Market size, by end-use, 2017 - 2028 (USD Million)
8.3.9 Italy
8.3.9.1 Market size, by technology, 2017 - 2028 (USD Million)
8.3.9.2 Market size, by product, 2017 - 2028 (USD Million)
8.3.9.3 Market size, by application, 2017 - 2028 (USD Million)
8.3.9.3.1 Market size, by infectious disease, 2017 - 2028 (USD Million)
8.3.9.4 Market size, by end-use, 2017 - 2028 (USD Million)
8.3.10 Spain
8.3.10.1 Market size, by technology, 2017 - 2028 (USD Million)
8.3.10.2 Market size, by product, 2017 - 2028 (USD Million)
8.3.10.3 Market size, by application, 2017 - 2028 (USD Million)
8.3.10.3.1 Market size, by infectious disease, 2017 - 2028 (USD Million)
8.3.10.4 Market size, by end-use, 2017 - 2028 (USD Million)
8.4 Asia Pacific
8.4.1 Market size, by country, 2017 - 2028 (USD Million)
8.4.2 Market size, by technology, 2017 - 2028 (USD Million)
8.4.3 Market size, by product, 2017 - 2028 (USD Million)
8.4.4 Market size, by application, 2017 - 2028 (USD Million)
8.4.4.1 Market size, by infectious disease, 2017 - 2028 (USD Million)
8.4.5 Market size, by end-use, 2017 - 2028 (USD Million)
8.4.6 China
8.4.6.1 Market size, by technology, 2017 - 2028 (USD Million)
8.4.6.2 Market size, by product, 2017 - 2028 (USD Million)
8.4.6.3 Market size, by application, 2017 - 2028 (USD Million)
8.4.6.3.1 Market size, by infectious disease, 2017 - 2028 (USD Million)
8.4.6.4 Market size, by end-use, 2017 - 2028 (USD Million)
8.4.7 Japan
8.4.7.1 Market size, by technology, 2017 - 2028 (USD Million)
8.4.7.2 Market size, by product, 2017 - 2028 (USD Million)
8.4.7.3 Market size, by application, 2017 - 2028 (USD Million)
8.4.7.3.1 Market size, by infectious disease, 2017 - 2028 (USD Million)
8.4.7.4 Market size, by end-use, 2017 - 2028 (USD Million)
8.4.8 India
8.4.8.1 Market size, by technology, 2017 - 2028 (USD Million)
8.4.8.2 Market size, by product, 2017 - 2028 (USD Million)
8.4.8.3 Market size, by application, 2017 - 2028 (USD Million)
8.4.8.3.1 Market size, by infectious disease, 2017 - 2028 (USD Million)
8.4.8.4 Market size, by end-use, 2017 - 2028 (USD Million)
8.4.9 Australia
8.4.9.1 Market size, by technology, 2017 - 2028 (USD Million)
8.4.9.2 Market size, by product, 2017 - 2028 (USD Million)
8.4.9.3 Market size, by application, 2017 - 2028 (USD Million)
8.4.9.3.1 Market size, by infectious disease, 2017 - 2028 (USD Million)
8.4.9.4 Market size, by end-use, 2017 - 2028 (USD Million)
8.5 Latin America
8.5.1 Market size, by country, 2017 - 2028 (USD Million)
8.5.2 Market size, by technology, 2017 - 2028 (USD Million)
8.5.3 Market size, by product, 2017 - 2028 (USD Million)
8.5.4 Market size, by application, 2017 - 2028 (USD Million)
8.5.4.1 Market size, by infectious disease, 2017 - 2028 (USD Million)
8.5.5 Market size, by end-use, 2017 - 2028 (USD Million)
8.5.6 Brazil
8.5.6.1 Market size, by technology, 2017 - 2028 (USD Million)
8.5.6.2 Market size, by product, 2017 - 2028 (USD Million)
8.5.6.3 Market size, by application, 2017 - 2028 (USD Million)
8.5.6.3.1 Market size, by infectious disease, 2017 - 2028 (USD Million)
8.5.6.4 Market size, by end-use, 2017 - 2028 (USD Million)
8.5.7 Mexico
8.5.7.1 Market size, by technology, 2017 - 2028 (USD Million)
8.5.7.2 Market size, by product, 2017 - 2028 (USD Million)
8.5.7.3 Market size, by application, 2017 - 2028 (USD Million)
8.5.7.3.1 Market size, by infectious disease, 2017 - 2028 (USD Million)
8.5.7.4 Market size, by end-use, 2017 - 2028 (USD Million)
8.6 Middle East & Africa
8.6.1 Market size, by country, 2017 - 2028 (USD Million)
8.6.2 Market size, by technology, 2017 - 2028 (USD Million)
8.6.3 Market size, by product, 2017 - 2028 (USD Million)
8.6.4 Market size, by application, 2017 - 2028 (USD Million)
8.6.4.1 Market size, by infectious disease, 2017 - 2028 (USD Million)
8.6.5 Market size, by end-use, 2017 - 2028 (USD Million)
8.6.6 Saudi Arabia
8.6.6.1 Market size, by technology, 2017 - 2028 (USD Million)
8.6.6.2 Market size, by product, 2017 - 2028 (USD Million)
8.6.6.3 Market size, by application, 2017 - 2028 (USD Million)
8.6.6.3.1 Market size, by infectious disease, 2017 - 2028 (USD Million)
8.6.6.4 Market size, by end-use, 2017 - 2028 (USD Million)
8.6.7 South Africa
8.6.7.1 Market size, by technology, 2017 - 2028 (USD Million)
8.6.7.2 Market size, by product, 2017 - 2028 (USD Million)
8.6.7.3 Market size, by application, 2017 - 2028 (USD Million)
8.6.7.3.1 Market size, by infectious disease, 2017 - 2028 (USD Million)
8.6.7.4 Market size, by end-use, 2017 - 2028 (USD Million)
Chapter 9 Company Profiles
9.1 Competitive dashboard, 2021
9.2 Becton, Dickinson and Company
9.2.1 Business overview
9.2.2 Financial data
9.2.3 Product landscape
9.2.4 Strategic outlook
9.2.5 SWOT analysis
9.3 Abbott (Alere)
9.3.1 Business overview
9.3.2 Financial data
9.3.3 Product landscape
9.3.4 Strategic outlook
9.3.5 SWOT analysis
9.4 BioMerieux SA
9.4.1 Business overview
9.4.2 Financial data
9.4.3 Product landscape
9.4.4 Strategic outlook
9.4.5 SWOT analysis
9.5 Eiken Chemical Co. Ltd
9.5.1 Business overview
9.5.2 Financial data
9.5.3 Product landscape
9.5.4 Strategic outlook
9.5.5 SWOT analysis
9.6 Hologic Inc. (Gen-Probe)
9.6.1 Business overview
9.6.2 Financial data
9.6.3 Product landscape
9.6.4 Strategic outlook
9.6.5 SWOT analysis
9.7 Lucigen
9.7.1 Business overview
9.7.2 Financial data
9.7.3 Product landscape
9.7.4 Strategic outlook
9.7.5 SWOT analysis
9.8 Meridian Bioscience, Inc.
9.8.1 Business overview
9.8.2 Financial data
9.8.3 Product landscape
9.8.4 Strategic outlook
9.8.5 SWOT analysis
9.9 OptiGene Limited
9.9.1 Business overview
9.9.2 Financial data
9.9.3 Product landscape
9.9.4 Strategic outlook
9.9.5 SWOT analysis
9.10 Qiagen NV
9.10.1 Business overview
9.10.2 Financial data
9.10.3 Product landscape
9.10.4 Strategic outlook
9.10.5 SWOT analysis
9.11 Quidel Corporation
9.11.1 Business overview
9.11.2 Financial data
9.11.3 Product landscape
9.11.4 Strategic outlook
9.11.5 SWOT analysis
9.12 Tecan Genomics Inc.
9.12.1 Business overview
9.12.2 Financial data
9.12.3 Product landscape
9.12.4 Strategic outlook
9.12.5 SWOT analysis
9.13 Thermo Fisher Scientific Inc.
9.13.1 Business overview
9.13.2 Financial data
9.13.3 Product landscape
9.13.4 Strategic outlook
9.13.5 SWOT analysis
9.14 Ustar Biotechnologies Ltd.
9.14.1 Business overview
9.14.2 Financial data
9.14.3 Product landscape
9.14.4 Strategic outlook
9.14.5 SWOT analysis
9.15 Grifols, S.A.
9.15.1 Business overview
9.15.2 Financial data
9.15.3 Product landscape
9.15.4 Strategic outlook
9.15.5 SWOT analysis
